Capstone Therapeutics says prior quarterly EPS figures should no longer be relied upon after share-count error
Reuters2026/08/12 11:34- Capstone Therapeutics flagged non-reliance on certain previously issued quarterly financial statements due to errors in weighted-average share counts.
- Issue affects basic and diluted net loss per share for quarters ended June 30, 2025, Sept. 30, 2025, and comparative March 31, 2025.
- Audit committee concurred on Aug. 10, 2026; amendments on Form 10-Q/A filed for June 30, 2025, Sept. 30, 2025, and March 31, 2026.
- Restated March 31, 2025 weighted-average shares to 1,555,566 from 5,190,251; net loss per share revised to $(1.56) from $(0.47).
- Management identified a material weakness in internal controls tied to EPS share-count computation; net loss and balance sheet amounts were not affected.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Faraday Future adds government procurement veteran Steven Newton as senior strategic advisor
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Crypto prices
More
